Recommended procedures for the classification of acute leukaemias. International Council for Standardization in Haematology (ICSH).
The classification of acute leukaemias is now widely based on a combined morphological, cytochemical and immunophenotyping approach. Difficulties are frequently encountered however in reaching an acceptable degree of diagnostic concordance between different laboratories because of variations in the techniques used (in terms of methodologies, reagents and equipment) and diagnostic interpretation. The International Council for Standardization in Haematology (ICSH) convened an expert panel to consider currently available diagnostic techniques with the aim of defining a minimum cytochemical and immunological diagnostic panel that could be used as core components for the classification of acute leukemia. The proposed ICSH scheme, which attempts to balance the basic requirement for providing precise and informative diagnostic information without limiting its use to only those laboratories with sophisticated facilities, is based on three sequential levels of investigation; primary cytochemistry, intracellular phenotyping and membrane immunophenotyping. The minimum ICSH recommended cytochemistries comprise myeloperoxidase (MPO), chloroacetate esterase (ChlorE) and alpha-naphthyl acetate esterase (ANAE), and standardised methods for these cytochemistries are detailed in this communication. For cases of acute leukaemia that remain unclassified by primary cytochemistry, subsequent immunological analyses for cytoplasmic CD3, CD22, MPO and nuclear TdT are recommended. The ICSH panel considers that the use of these minimum primary cytochemical and intracellular phenotyping procedures will lead to the consistent classification of most acute leukaemias, and that the third level of investigation (membrane immunophenotyping) should be used for the purposes of confirmation, diagnostic clarification of atypical leukaemias, and the subtyping of acute lymphoblastic leukaemias (ALL). The ICSH panel also recognised that there are a number of additional technologies which can provide definitive diagnostic information, such as cytogenetics and DNA genotyping, but these were excluded from the minimum panel because of their restricted availability. While many specialised laboratories, particularly in the areas of diagnostic research, will continue to use individual investigatory protocols, it is considered that the inclusion of the ICSH scheme as core components would lead to greater consistency when comparing independent studies of acute leukemia.
Scott
C S
CS
Haematological Malignancy Diagnostic Service, Leeds General Infirmary, England, UK.
Den Ottolander
G J
GJ
Swirsky
D
D
Pangalis
G A
GA
Vives Corrons
J L
JL
de Pasquale
A
A
van Hove
L
L
Bennett
J M
JM
Namba
K
K
Flandrin
G
G
D000208:Acute Disease; D002265:Carboxylic Ester Hydrolases / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D007938:Leukemia / Q000145:classification* / Q000201:enzymology / Q000276:immunology; D009283:Naphthol AS D Esterase / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism
D009195:Peroxidase; D009283:Naphthol AS D Esterase; D002265:Carboxylic Ester Hydrolases; C019873:chloroacetate esterase